FRM
ENTA icon

Fox Run Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Fox Run Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$250K Buy
20,501
+10,319
+101% +$138K 0.04% 685
2025
Q4 		$161K Buy
+10,182
New +$129K 0.02% 828
2016
Q3 		– Sell
-9,800
Closed -$216K – 537
2016
Q2 		$216K Sell
9,800
-1,000
-9% -$26.2K 0.1% 410
2016
Q1 		$317K Buy
+10,800
New +$301K 0.21% 209

Other funds holding ENTA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
SSC
Spruce Street Capital New York $416M AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Fox Run Management's ENTA Position: Q1 2026 in Review

Fox Run Management increased its Enanta Pharmaceuticals (ENTA) stake by 101% in Q1 2026, buying an estimated $138K and bringing the position to 20,501 shares worth $250K. The position accounts for 0.04% of the portfolio, ranked #685.

Fox Run Management first reported a position in ENTA in Q1 2016 and has held it in 4 quarters since. The position peaked at $317K in Q1 2016. 132 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.

  • Fox Run Management held 20,501 shares of Enanta Pharmaceuticals worth $250K as of Q1 2026.
  • Fox Run Management bought 10,319 Enanta Pharmaceuticals shares in Q1 2026, an estimated $138K.
  • Enanta Pharmaceuticals made up 0.04% of Fox Run Management's portfolio in Q1 2026, its #685 holding.
  • Fox Run Management first reported a position in Enanta Pharmaceuticals in Q1 2016 and has held it in 4 quarters since.
  • Fox Run Management's Enanta Pharmaceuticals position peaked at $317K in Q1 2016.
  • 132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.

Based on Fox Run Management's 13F filing for Q1 2026, filed 12 May 2026.